Chilean biotech Botanical Solution Inc. (BSI) secured an additional $7.6M in a Series A extension round, bringing its total funding to $23.3M.
BSI will use the funding to expand production of QS-21, a vaccine adjuvant, and invest in R&D, including expanding its laboratories in Davis, California, to ensure a steady supply of QS-21.
QS-21 is a crucial component in FDA-approved shingles and respiratory syncytial virus (RSV) vaccines. BSI’s tissue culture method, derived from cultivated quillaja plants, will open further opportunities for vaccine developers.
BSI provides botanical solutions for the pharmaceutical and agricultural sectors aiming to capitalize on the growing global market for botanical ingredients, which is projected to reach $312.6B by 2033.
Read more on: Tekios.